Long-term effects of breast cancer treatment on heart function

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the long-term cardiac outcomes in female breast cancer survivors who received chemotherapy and/or radiotherapy. It will include participants from a previous study who were diagnosed with stage I-III breast cancer at least five years ago. The study will utilize echocardiography to assess cardiac function and determine if mild cardiac dysfunction observed in previous research predicts further deterioration. The findings could help clarify the risks associated with breast cancer treatments and inform clinical guidelines.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who previously took part in de BLOC-I study will be included. These criteria were:
* females diagnosed with stage I-III BC at least five years ago or local or locoregional recurrence of BC at least five years ago
* treatment with chemotherapy and/or radiotherapy.

Exclusion Criteria:

* Patients unfit to travel to the hospital due to severe mental or physical illness, based on assessment by their GP.

Exclusion criteria for the BC survivors in the BLOC-I study were:

* metastatic disease at the time of BC diagnosis;
* BC treatment after 80 years of age;
* history of treatment for other types of cancer.

Where it's running

• University Medical Center Groningen
  Groningen, Netherlands Recruiting

Study contacts

• Study coordinator: Daan Brandenbarg, PhD
• Email: d.brandenbarg@umcg.nl
• Phone: 0031628475305

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Sacubitril/Valsartan to prevent heart damage in breast cancer treatment

  This study is testing if the medication Sacubitril/Valsartan can help protect the hearts of women undergoing treatment for breast cancer from damage.

  Recruiting at 3 sites Phase 4 Silesian Centre for Heart Diseases · Opole, Opole Voivodeship and 3 other locations · NCT05465031

• Machine-learning prediction of heart damage from anthracycline or HER2 cancer therapies

  We will see if a machine-learning score can predict which adults starting anthracycline or HER2-targeted cancer therapies will develop heart damage within one year.

  Recruiting University Hospital, Caen · Caen · NCT07191730

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• AI-based assessment of heart function using ECG wearable monitors

  This study tests if a new AI tool using a wearable heart monitor can accurately check heart function in people with heart failure compared to traditional heart scans.

  Recruiting at 8 sites Peerbridge Health, Inc · Orange, California and 7 other locations · NCT06699056

• Ultra-high-frequency ECG to diagnose ventricular electrical dyssynchrony in patients getting pacemakers

  This test checks whether an ultra-high-frequency ECG can safely and accurately detect ventricular dyssynchrony in adults with bradycardia or heart failure who are having their first pacemaker implanted.

  Recruiting at 12 sites VDI Technologies · Avondale, Arizona and 11 other locations · NCT06641362

• Exercise and fitness program for breast cancer survivors to improve heart health

  This study tests whether a special exercise and yoga program can help breast cancer survivors over 60 improve their heart health and physical fitness after treatment.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06595147

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.